The recognition that obstructive disease of the epicardial coronary arteries, causing ischaemic heart disease, can be treated with a percutaneous coronary intervention (PCI) has been a major discovery in cardiology in the last 40 years contributing, in particular, to the reduction of mortality associated to acute myocardial infarction (AMI). However, even in the era of drug-eluting stent (DES) implantation, a sizable proportion of patients who undergo PCI may develop late or very late post-implantation complications, that occur in the form of restenosis, neoatherosclerosis, and/or in-stent thrombosis. Such complications are clinically relevant since they can cause AMI and negatively impact on the outcome. The underlying pathophysiological mechanisms are complex but related to inhibition of neointimal proliferation by DES that, on the hand, reduces the rate of in-stent restenosis, but, on the other hand, causes dysfunctional vessel healing, persistent inflammation, platelet activation, and adverse immunological responses. Multiple approaches have been developed or are under evaluation to target DES-related complications including pharmacotherapy, procedure-related imaging methods, novel stent designs, and drug-delivery methods. The aim of this review is to provide an update on the latest preclinical, translational, and clinical pharmacotherapeutic developments in this setting that target novel cellular mechanisms and pathways that might contribute to neoatherosclerosis. Due to the importance of secondary prevention in the reduction of DES-associated complications, this review also provides a short overview of pharmacological agents that are established or currently being investigated in this regard.
Introduction
While the introduction of drug-eluting stent (DES) technology for the treatment of significant culprit lesions due to coronary artery disease (CAD) was able to markedly reduce neointimal proliferation, at the same time, a high price was paid in terms of delayed and aberrant arterial healing, due to the effects of anti-proliferative drugs eluted by the stent that impaired physiological re-endothelialization and vascular remodelling. 1, 2 Autopsy reports and experiments in animal models also showed that persistent fibrin deposition, chronic inflammation, and continuous platelet activation characterize delayed arterial healing. 3 Most of the current DES implants inhibit the mammalian target of rapamycin (mTOR) that is a member of the phosphatidylinositol 3-kinase-related kinase (PIKK) family of serine/threonine protein kinases. 4, 5 Recently, an interaction between the FKBP12.6 cellular pathway and canonical mTOR inhibitors was discovered as a major cause of vascular permeability and neoatherosclerosis showing that more precise molecular targeting of mTOR complex might ameliorate late complications of interventional treatment such as neoatherosclerosis. 6 Generally, an impaired coronary endothelial function and vasomotion associated to DES implantation is characterized by decreased nitric oxide (NO) production, loose intercellular junctions and decreased levels of antithrombotic mediators, processes that are paralleled by a rapid infiltration, retention, and increased expression of foamy macrophages within the neointima of stented segment thus promoting the formation of a new atheroma. 7 Furthermore, wall shear stress and local haemodynamic forces also play a role in restenosis, thrombosis, and platelet activation after stent implantation. 8 In this review, the role of neoatherosclerosis and other late or very late stent complications that occur post-DES implantation are discussed in the context of established risk factors and potential therapeutic targets, with emphasis on novel cellular pathways.
Neoatherosclerosis as a late or very late complication of interventional treatment Definition of neoatherosclerosis, its incidence and incidence of late stent complications
As the design in stent technology evolved over time, different profiles of clinical complications after stent implantation were observed, corroborated by robust follow-up data. Namely, 1st generation DES implants were able to substantially reduce in-stent restenosis (ISR) events associated with bare-metal stents (BMS), whereas increasing the incidence of in-stent thrombosis (IST). 9 Notably, ISR occurs earlier in patients implanted with BMS, neointimal hyperplasia (proliferation and migration of vascular smooth muscle cells, VSMC) being the prevalent mechanism. Furthermore, 2nd generation DES implants were associated with lower rates of IST compared with 1st generation DES, however, a different type of complication leading to late or very late stent failure came to prominence with newer implants, known as 'neoatherosclerosis'. [10] [11] [12] This distinct type of accelerated atherosclerosis of multifactorial aetiology develops inside of the stented segment of a coronary vessel. [13] [14] [15] Neoatherosclerosis seems to marked by three distinct phases that encompass early infiltration by foamy macrophages, instent atherosclerotic plaque development, and formation of necrotic core plaque with a thin fibrous cap. 16 Moreover, among 2nd generation DES implants, differences were observed in terms of tissue characteristics in early (<1 year) and late (>1 year) ISR-former being mediated mainly by neointimal hyperplasia, while neoatherosclerosis was the dominant mechanism in the latter. 17 Specifically, late ISR was characterized by higher prevalence of lipid-laden neointima, thin-cap fibroatheroma, neovascularization, and macrophage infiltration compared with early ISR and it could be inferred that the delayed arterial healing associated with DES implants might predispose to neoatherosclerosis. As a consequence of late stent failure neoatherosclerosis occurs more frequently in DES than BMS largely due to stent underexpansion, and nowadays is recognized as a late or very late complication of a coronary interventional treatment. [18] [19] [20] [21] This was confirmed by the autopsybased study that revealed significantly higher incidence of neoatherosclerosis in DES (31%) compared with BMS (16%) with significantly shorter median stent duration in the former. 18 Moreover, development of neoatherosclerosis in DES implants has been described as a late catch-up phenomenon due to observation that neointimal growth is highly suppressed during the 1st year after DES implantation but then shows continuous progression accompanied with rapid deposition of lipid-laden macrophages thus acting as a final common pathway of late stent failure. 22 Indeed, an optical coherence tomography (OCT) registry-based study examining very late stent failure mechanisms among early-and new-generation DES revealed that three most common causes of very late DES failure were strut malapposition (34.5%), neoatherosclerosis (27.6%), and uncovered struts (12.1%). 23 A graph showing the percentage of atherosclerotic change and neoatherosclerosis incidence in DES compared with BMS in relation to implant duration in months is provided in Figure 1 .
Risk factors associated with neoatherosclerosis
While series of intracoronary imaging studies encompassing intravascular ultrasound (IVUS) and OCT along with direct histopathological analyses from biopsy tissue specimens provided a morphological and compositional characterization of neoatherosclerosis, its aetiology and pathophysiology remain largely unknown. 11, 18, 24, 25 Some OCT observations suggest that neoatherosclerosis occurs regardless of stent type and is more dependent on focal triggers within the vessel that are involved in the formation of vulnerable lesions. 26, 27 Some relevant differences in pathological mechanisms between native coronary atherosclerosis and in-stent neoatherosclerosis, as well as representative OCT images, are provided in Figure 2 .
The dominant hypothesis about the neoatherosclerosis formation is based on the assumption that neointimal proliferation develops de novo within the stent, independently of underlying native plaque; however, this notion is based on a snapshot morphological lesion analysis and has recently been challenged. 28, 29 The pathogenic mechanisms at the basis of neoatherosclerosis might indeed be similar to those involved in native atherosclerosis progression (e.g. endothelial dysfunction, lipid uptake, inflammation, etc.). An elegant study by Taniwaki et al.  24 recently showed a significant association between in-stent neoatherosclerosis and the progression of native coronary atherosclerosis, assessed as change in minimal lumen diameter (MLD) serially measured within matched coronary segments at baseline and 5-year angiographic follow-up. This study showed a significantly greater reduction in MLD in both target and non-target vessel in patients with in-stent neoatherosclerosis than in those without, suggesting a pathogenic link between the two processes. These findings appear even more relevant considering the relatively low incidence of neoatherosclerosis (i.e. 16% of lesions in the study by Taniwaki) and the need for long-term follow-up in these patients. 24 Importantly, the increased presence of neoatherosclerosis is not only associated with individual atherosclerosis risk factors and underlying comorbidities, but largely with non-traditional risk factors of which most are inherent to stent design, anatomical complexity of the lesion (bifurcations, trifurcations, long lesions, small vessels, etc.), local vessel haemodynamics, and percutaneous coronary intervention (PCI)-related procedural variables (stent underexpansion, malapposition, fracture, flow-limiting dissection, and similar). An association of neoatherosclerosis with neovascularization and adjacent lipid plaque has also been established. 30 A comprehensive overview of risk factors associated with neoatherosclerosis is provided in Table 1 . 
stress (ESS)
, which is the tangential force generated by the friction of the flowing blood on the surface of the vessel wall, affects atherosclerotic disease progression in both native and stented coronary arteries. 31 Several studies suggest that low ESS promotes plaque growth and vulnerable plaque formation in humans. 32 As the pathogenic mechanisms at the basis of neoatherosclerosis appear to be similar to those involved in native atherosclerosis progression (e.g. endothelial dysfunction, lipid uptake, inflammation, etc.), it is conceivable that flow dynamics and ESS play an important role in the development of neoatherosclerosis after stent implantation. Papafaklis et al. 33 reported an inverse correlation between ESS and neointimal hyperplasia in BMS and in first-generation DES. An OCT study showed that in-stent neoatherosclerosis occurs more often at the inner curvature and at the outer waist of a bifurcation, which are typically exposed to low and oscillatory shear stress. 34 A virtualhistology intravascular ultrasound (VH-IVUS) study by Bourantas et al. 35 showed a negative correlation between predominant ESS and the percentage of the neointimal necrotic core component, which is indicative of the presence of neoatherosclerosis, in BMS. Finally, systemic inflammation and allergic inflammation as reactions to a foreign body are biologically important processes that occur after stent implantation and are associated with restenosis, stent thrombosis, and degree of neointimal lesion burden.
36-39

Pathophysiology of neoatherosclerosis and its clinical implications
Mechanisms of neoatherosclerosis and accelerated plaque formation after DES implantation are poorly elucidated, and there is still a substantial lack of knowledge regarding the underlying mechanisms and causal factors. Recently, the role of lipid droplet-associated proteins such as those belonging to Perilipin family of proteins has been investigated in the context of atherogenesis. These proteins have a role in the excess accumulation of intracellular lipids and are linked to metabolic diseases, obesity, Type 2 diabetes and atherosclerosis. 40 Recently, the role of adipophilin, also known as perilipin 2 or adipose differentiation-related protein (ADRP) has been implicated in the development of ISR due to neoatherosclerosis among patients implanted with 2nd generation DES. Of note, perilipin protein levels were significantly higher in peripheral blood mononuclear cells (PBMCs) of patients with in-stent neoatherosclerosis and implanted DES compared with patients with native CAD. 41 Since rapid formation of lipid-laden neointima and extensive infiltration of foamy macrophages at the stent lesion site are histopathological hallmarks of neoatherosclerosis, as previously elaborated, it is plausible that increased lipid retention and accumulation within resident macrophages and circulating monocytes that are being increasingly recruited to the lesion site are potential mechanisms involved in neoatherosclerosis formation and/or progression. Such effect might indeed be mediated by proteins, such as perilipin 2, that are involved in the regulation of cytoplasmic lipid droplets within macrophage foam cells and storage of cholesteryl esters derived from modified lipoproteins. 40, 42 Recently, experimental induction of perilipin 2 deficiency and a concomitant increase in extracellular plasma cholesterol acceptors such as apolipoprotein A-I (apoA-I) and highdensity lipoprotein cholesterol cumulatively reduced lipid droplets and cholesterol ester content in cultured macrophages and significantly reduced atheroma formation. 43 MicroRNA-based strategies in addressing complications of interventional treatment
Current drug delivery solutions available with modern stents fail to selectively suppress proliferation of VSMCs without a negative impact on the growth of endothelial cells (ECs) within the vasculature. To overcome this issue, small non-coding RNA molecules that are able to distinctively regulate VSMCs and ECs might provide a viable solution. These molecules exert such effects through posttranscriptional silencing, degradation or overexpression of genes, and their downstream end-products that are involved in vascular remodelling. 44, 45 MicroRNAs could be utilized for the selective inhibition of VSMC proliferation, platelet activation, and improvement of endothelial regeneration after stent deployment. 46 In fact, a selective miRNA-based strategy was able to markedly reduce restenosis, hypercoagulability and improve re-endothelialization, and vasodilatory response to acetylcholine in the preclinical model of vessel injury thus confirming the potential of this therapeutic approach in restricting or abolishing restenosis. 47, 48 In the clinical practice, late stent failure due to neoatherosclerosis and stent thrombosis is a relevant problem, because these events are associated with higher rates of fatal and non-fatal acute coronary syndromes (ACS) and of overall poor clinical outcomes. [49] [50] [51] Moreover, neoatherosclerosis is a frequent OCT finding in late or very late stent thrombosis. 14, 23, 52 Due to an increasing number of PCI procedures performed worldwide and currently unmet need in ISR prevention, it is expected that significant numbers of late stent failure events will occur in the future thus portending poor clinical outcome. Risk factors associated with the occurrence of neoatherosclerosis along with available therapeutic pathways that could mitigate neoatherosclerosis formation and/or progression are summarized in Figure 3 .
Stent-based strategies and procedural factors in the context of neoatherosclerosis
During the last decade, DES implants have undergone substantial structural improvements, including thinner metallic struts and more biocompatible durable or biodegradable polymers thus often being labelled as 'third generation' DES. These modifications have led to an improved healing response and reduced failure potential compared with 1st-and 2nd generation DES. 53 Stent design has a significant impact on flow dynamics in stented coronary segments. Thick struts affect local ESS, favouring the development of flow disturbances with low and oscillatory ESS, which may in turn activate the regenerating endothelium towards a pro-inflammatory phenotype and favour lipid uptake. 54 This may induce unfavourable healing response and development of neoatherosclerosis, although further studies are needed to confirm this hypothesis. On the other hand, thinner struts may showed a similar healing response after 3 months and incidence of NA after 18 months between a biodegradable polymer everolimuseluting stent and a durable polymer zotarolimus-eluting stent. In another study, the rate of in-stent neoatherosclerosis within biodegradable polymer biolimus-eluting stents was similar to bare metal stents, and tended to be lower than in durable polymer sirolimus-eluting stents.
57
Furthermore, bioresorbable vascular scaffolds (BVS) were developed to only temporarily cover the diseased coronary segment followed by full biodegradation, potentially overcoming the long-term issues of metallic stents. However, randomized trials consistently observed worse long-term clinical outcomes of the Absorb BVS compared with metallic new-generation DES, both in terms of device-oriented adverse events and device thrombosis, particularly after 1 year. The international INVEST registry identified neoatherosclerosis as one of the main mechanisms underlying very late scaffold thrombosis, being observed in about 18% of lesions at 2-year followup. 58 More recently, Moriyama et al. conducted a study with serial
OCT imaging performed at baseline, 1 year, and 5 years after Absorb BVS implantation in 20 patients with 22 lesions. Neoatherosclerosis, defined as lipid-laden plaque including thin-cap fibroatheroma with or without intimal rupture and/or thrombi, and/or calcific plaque with or without neovascularization and/or macrophage accumulation, was identified in 100% of lesions at 5 years after BVS implantation.
59
Multiple pathogenic factors have been suggested, including endothelial dysfunction, inflammation, and local blood flow alterations related to the scaffold strut size (i.e. thick struts), geometry, and large polymer load of BVS. Further studies are needed to clarify these potential mechanisms, and to identify the incidence of neoatherosclerosis after implantation of BVS other than the Absorb BVS.
60
While the data corroborate that ABSORB BVS is a reasonably safe platform, it did not fulfil the promise of abolishing or reducing neoatherosclerosis and/or stent thrombosis. However, novel approaches in BVS polymer design that are under development might mitigate these late PCI complications. Of note, BVS with polymers based on poly-L-lactic acid (PLLA) might support beneficial vascular remodelling in humans without detected neoatherosclerosis at 2 years, even in the absence of antiproliferative drugs. 61 Previous preclinical studies on novel ultrahigh molecular weight amorphous PLLA BVS implants demonstrated expansive vascular remodelling in PLLA BVS and this biological phenomenon appeared independently of antiproliferative drugs. 62, 63 Furthermore, an addition of magnesium to BVS was associated with decreased thrombogenicity, less platelet adhesion, and inflammatory cell deposition in porcine arteriovenous shunt model, compared with BMS. 64 In humans, a 12-month follow-up after implantation of the 2nd generation BVS with magnesium backbone showed a favourable safety profile and stable angiographic parameters between 6 and 12 months. 65 However, caution has to be exercised since De la Torre Hernandez et al. 66 recently demonstrated that the arterial healing process after implant deployment could be more device-specific rather than patient-specific, suggesting that not all BVS scaffolds might act in the same manner in the long-term. For this reason, future studies on newer generation magnesium-and PLLA-based scaffolds are, indeed, warranted to assess their effects on clinical endpoints during longer follow-up, particularly compared with established 'workhorse' DES platforms.
67,68
Regarding the procedural PCI factors that might contribute to the formation of neoatherosclerosis, an OCT imaging provides accurate stent sizing and guidance of the stenting strategy, by providing both information on the lumen dimension and lesion characteristics. 69 Even more, latest European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) guidelines on myocardial revascularization support the use of OCT imaging in cases dealing with an in-stent neoatherosclerosis and further procedure planning.
70 Post-PCI OCT imaging allows strut-level evaluation of the stent deployment and provides guidance for stent optimization. Optical coherence tomography is able to identify correctable abnormalities related to the stent and the underlying vessel wall, such as stent underexpansion, strut malapposition, and geographic plaque miss. 70 Stent underexpansion is a major predictor of early stent thrombosis or restenosis, however, no definite pathogenic link exists between acute strut malapposition and subsequent events. 70 In contrast, OCT studies investigating the mechanisms of stent thrombosis have consistently identified strut malapposition as a frequent underlying finding. 23 Whether stent optimization using an OCT imaging may impact on the development of neoatherosclerosis at follow-up remains unknown, and need to be demonstrated in future studies.
Pharmacotherapeutic strategies in the prevention of neoatherosclerosis Role of antiproliferative drugs and the mode of drug delivery
Sirolimus seems to reduce the amount of positive cell cycle regulators and increase the amount of cell cycle inhibitors, leading to inhibited cell migration, proliferation, and desensitization of the cells to the effects of low ESS. 1 Because durable polymers result in long-term drug sequestration within the polymer with prolonged drug delivery over time, this may result in long-term endothelial dysfunction. It seems plausible that limiting the duration of exposure of the arterial wall to mTOR inhibitors may result in a limited long-term endothelial dysfunction and perhaps decreased neoatherosclerosis though this is unproven to date.
71
In the absence of definitive clinical data demonstrating differences between durable polymer DES (DP-DES) vs. bioresorbable polymer DES (BP-DES) in terms of neoatherosclerosis, it is worth discussing what some of the advantages of the latter might be and why improvement in DES design is still necessary. As alluded to earlier, the genesis of late restenosis and neoatherosclerosis remains unknown but studies suggest it may be related to long-term effects on endothelium caused by -limus mTOR inhibitors used in the current generation DES. Long-term exposure of ECs to sirolimus leads to endothelial barrier dysfunction allowing entrance of lipoproteins and immune cells into the arterial wall, similar to the pathogenesis of native vessel atherosclerosis. 72 Moreover, because drug tissue levels tend to Antiplatelet and lipid-lowering therapy in the context of drug-eluting stent implantation
Pharmacotherapeutic secondary prevention encompassing lipid reduction and inhibition of platelet activation, pathological processes that are both implicated in neoatherosclerosis, is exceptionally important after DES implantation. The ESC guidelines clearly emphasize the importance of these therapies after coronary revascularization. [74] [75] [76] The optimal duration of dual antiplatelet therapy (DAPT) with aspirin and a thienopyridine (ADP receptor/P 2 Y 12 inhibitor) and/or addition of anticoagulants probably need to be calibrated on a personalized assessment of patients' coronary anatomy, comorbidities, and ischaemic/bleeding risk.
75,77,78
Similarly, patients with ACS that underwent PCI are recommended to reach lower targets of low-density lipoprotein (LDL) cholesterol compared with conventional patients with hyperlipidaemia. 79 However, these goals are often unmet in population of ACS patients due to statin intolerance or refractoriness to LDL cholesterollowering despite optimal high-potency statin therapy or statin combined with the intestinal cholesterol inhibitor ezetimibe. Due to residual cholesterol and inflammatory risk in these patients, therapies that would provide additional reduction in circulating levels of LDL cholesterol and proinflammatory mediators and would contribute to a greater plaque stabilization are required. 80 Recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors were shown to increase recycling of LDL cholesterol receptors, therefore, efficiently lowering concentrations of LDL cholesterol in circulation beyond the effects of standard therapy. 81 In the context of CAD, GLAGOV trial showed that PCSK9 inhibition on top of statin treatment was associated with a significant additional reduction of plaque burden in patients with CAD, compared with patients that were using statins only. 82 This aggressive lipid-lowering treatment with PCSK9 inhibitors might have an impact on lipid-related neoatherosclerosis and plaque stabilization since higher levels of matured PCSK9 were associated with coronary spotty calcifications in ACS patients and this concept was also confirmed in a preclinical study by Goettsch et al.
83,84
Finally, precision-tuning of the lipid-lowering therapies might be based on the plaque imaging (i.e. assessment of fibrous cap thickness in vulnerable plaque lesions, quantification of plaque burden) and geometric characterization of the vessel architecture at lesions of interest (i.e. minimal luminal area, etc.) in each individual patient as advanced imaging techniques become more routinely used in the clinical practice.
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Interleukin-1/interleukin-6/C-reactive protein pathway
The inflammation is an important driver of healing responses after stent implantation. 86 Therefore, targeting proinflammatory pathways, while exerting immunosuppressive effects seems as a reasonable therapeutic approach to prevent ISR and late complications of interventional treatment. 87 The pivotal CANTOS trial demonstrated that inflammatory pathogenesis of atherosclerosis is a validated concept showing that the inhibition of interleukin-1 beta (IL-1b) with a therapeutic monoclonal antibody canakinumab, without affecting lipid levels, in patients with previous acute myocardial infarction (AMI) and C-reactive protein (CRP) levels >2 mg/L was able to significantly lower the composite outcome of MI, stroke or death by 15%, and secondary endpoint that included urgent revascularization by 17%, compared with placebo. 88 This notion was confirmed in a study by Chibana et al. 89 showing that, in patients implanted with the mTORinhibitor-eluting stent, sirolimus increased IL-1b mRNA expression and increased IL-1b release within coronary artery smooth muscle cells (CASMCs) implicating that serum IL-1b levels could serve as a biomarker for DES-associated coronary endothelial dysfunction. Perhaps such effects of inflammation-directed pharmacotherapy that inhibits IL-1b pathway could extend to the suppression of neoatherosclerosis due to the implicated role of this cellular pathway in foam cell formation and induction of interleukin-6 (IL-6) in human ECs.
90
Anti-inflammatory agents might indeed ameliorate residual risk among patients that survived AMI since standard pharmacotherapy including high-dose statin regimen is often insufficient in preventing recurrent ischaemic events or death.
91
The pharmacological blockade of other mediators of inflammation such as interleukin-6 receptors (IL-6R), CC2 chemokine receptors, and CD20 might also prove as viable strategies in the future therapeutic targeting of vascular inflammation and atherothrombosis prevention. So-called C-reactive protein (CRP)/IL-6/IL-1 axis recently became a research hotspot in the anti-inflammation secondary prevention pharmacotherapy with agents such as low-dose methotrexate and low-dose colchicine being currently investigated in clinical trials for the purpose of reducing cardiovascular events.
93-95 A role of NLRP3 inflammasome that is activated by cholesterol crystals and implicated in atherosclerosis has been increasingly studied with a potential of well-known 'old' agents such as colchicine finding a new role in cardiovascular applications. 96 A recent study by Vaidya et al. 97 showed that the addition of low dose colchicine (0.5 mg/day), which inhibits cholesterol crystal-induced activation of inflammasome, to optimal medical therapy was associated to a significant reduction of plaque volume at coronary computerized-tomography (CCT) and of hs-CRP levels among patients with recent ACS (<1 month), compared with optimal medical treatment only. This study showed that colchicine might be a valuable addition to secondary prevention armamentarium in patients that suffered ACS and because of its antiinflammatory properties, it is plausible that colchicine could mitigate some of the complications of DES implantation. However, to establish whether these beneficial effects of colchicine on surrogate endpoints translate into a benefit on clinical outcomes remains to be investigated.
98
NF-jB pathway
Nuclear factor kappa-light-chain-enhancer of activated B cells (NFjB) pathway is an intracellular signal transduction system that is implicated in multiple inflammatory disorders, cancer proliferation, innate immunity, cellular apoptosis, and differentiation. 99 It is a rapid-acting and pleiotropic transcription factor meaning that it is ubiquitously Previously, a link between NF-jB pathway and atherosclerosis has been established, involving all stages of atheroma development, starting with plaque formation and subsequent destabilization and rupture.
107,108 Additionally, NF-jB pathway activation is involved in lipid metabolism, foam cell formation, vascular inflammation, proliferation of VSMCs, arterial calcification, cardiac fibrosis, and plaque progression making it as a worthwhile therapeutic target in cardiovascular disease. [109] [110] [111] [112] In the preclinical model, inhibition of NF-jB pathway abolished induction of adhesion molecules in ECs, impaired macrophage recruitment to atherosclerotic lesions and significantly decreased expression of proinflammatory cytokines and chemokines in aorta thus clearly demonstrating that NF-jB signalling is an important cross-talk mediator of atherosclerosis and its therapeutic blockade could portend myocardial protection. 113 In this respect, the use methotrexate, an immunosuppressive and antimetabolic agent that inhibits T-cell activation, intracellular adhesion molecule expression, folate metabolism and methyltransferase activity and selectively down-regulates B-cells expression has been recently examined in terms of potential cardiovascular pharmacological applications. 114, 115 Importantly, methotrexate blocks the binding of interleukin-1b (IL-1b) to interleukin-1 receptors (IL-1Rs) and Finally, methotrexate suppresses TNF-induced NF-jB pathway activation by inhibition of NF-jB-dependent reporter gene expression. 118 Another mechanism by which methotrexate decreases basal levels of NF-jB activity is through increased expression of long intergenic (noncoding) RNA-p21 levels via DNA-dependent protein kinase catalytic subunit (DNA PKcs)-dependent mechanism.
119
Furthermore, adenosine selectively suppressed TNF-induced NF-jB activation in different cell types. 120 Mechanisms of methotrexate interaction with NF-jB pathway are illustrated in Figure 4 . Stent-based methotrexate delivery in a porcine coronary artery was able to effectively attenuate peristrut inflammation and neointimal hyperplasia.
121 Favourable effects of methotrexate on the formation of neoatherosclerosis in a rabbit model of atherosclerosis with implanted DES were recently reported. 122 In humans, a recent clinical study that involved patients with elective PCI showed that low dose (5 mg/week) of oral methotrexate administration before and after the procedure was safe and no cases of clinical restenosis were reported at 9-month follow-up, however, BMSs were used in this setting.
123
Finally, it seems that therapies such as colchicine and methotrexate have a potential of lowering cardiovascular risk through immunomodulation. 124 If these effects might extend to complications of the coronary interventional treatment such as neoatherosclerosis remains to be determined. TREM-1 blockade by an experimental pharmacological agent is also presented.
Neoatherosclerosis after drug-eluting stent implantation disease, septic shock, and ischaemic myocardial injury. Due to these established implications of TREM-1 signalling in cardiovascular pathology, a study by Wang et al.
132 enrolled 130 patients with angiography-determined ISR and age-and gender-matched control group of 150 patients without ISR that were finally selected among the pool of 1683 patients that underwent PCI. This study showed that sTREM-1 levels in serum were significantly increased in patients with angiography-determined ISR when compared with controls. Furthermore, blockade of TREM-1 with a synthetic inhibitory peptide LP17 significantly inhibited while TREM-1-activating antibody promoted increased proliferation, migration of VSMCs, and cellular inflammation. This study told us two important things-sTREM-1 levels in serum might reflect the presence and degree of ISR among patients that underwent stent implantation thus serving as a predictive biomarker in this setting and on the other hand, pharmacological inhibition of TREM-1 might help in attenuating restenosis progression. Interestingly, TREM-1 expression in macrophages is regulated at transcriptional level by NF-jB pathway that was previously elaborated in this review and experimental data showed that cellular treatment with inhibitors of NF-kB was able to abolish the expression of message of TREM-1 induced by bacterial stimuli. 133 Mechanism of TREM-1 pathway and its interaction with NF-kB pathway are depicted in Figure 5 . Taken together, preclinical and clinical data on TREM-1 warrant further investigations of this peptide in the ACS setting and in the risk management/monitoring for complications after stent implantation.
Future perspectives
It becomes evident that research directed towards novel stent systems and adjunct pharmacological solutions will mark the upcoming era of cardiovascular science, as we delve deeper in the pathophysiology and vascular biology of CAD and both local and systemic immunoinflammatory responses that are associated with the nature and complications of interventional treatment. In this regard, the systemic administration of low-dose immunosuppressive and antiinflammatory pharmaceutical agents seems as an attractive concept that showed some promise in modifying the course and complications of atherosclerotic disease. How these effects will translate to patient bed and real-life clinical outcomes remain to be seen in the upcoming trials, especially those conducted in the secondary prevention setting.
Conclusions
While tremendous improvements have been made in minimizing the late complications of coronary interventional treatment, risks of neoatherosclerosis, and late stent failure are still present, requiring the skilful precision tailoring of antiplatelet and anti-inflammation pharmacotherapy combined with the appropriate stent choice placed in the correct vessel with correct apposition, size, and expansion in the correctly-selected patient. Local delivery of the pharmaceutical agent to the site of the lesion that will secure long-term patency with preserved endothelial function remains to be the quest for the interventionalist's Holy Grail. This quest will remain even more complicated with challenges in reducing hyperlipidaemia, suppressing inflammation, slowing physiological drivers of thrombosis and finally, recognizing the residual cardiovascular risk among patients with a significant CAD and high comorbidity burden that underwent PCI.
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